Business Model Breakdown
How Abivax SA Makes Money
ABVX
Market Cap
$8.3B
Annual Revenue
$520,000
Employees
69
The Short Version
Abivax SA is a clinical-stage biotechnology company that focuses on developing novel immune-modulating therapies for chronic inflammatory diseases. Currently, its primary business involves conducting research and development for its lead drug candidate, obefazimod, in late-stage clinical trials for Ulcerative Colitis (UC) and Crohn's Disease (CD). The company is pre-revenue from drug sales and relies on capital raises and collaborations to fund its extensive R&D efforts. If obefazimod receives regulatory approval, its business model will pivot to commercializing and selling the drug to patients through healthcare systems globally, generating revenue from product sales.
Where the Revenue Comes From
Operating income (e.g., grants, collaborations, licensing - currently €4.6M in FY25)
Future product sales of obefazimod (if approved)
Who buys: Patients suffering from chronic inflammatory diseases like Ulcerative Colitis and Crohn's Disease, prescribed by gastroenterologists and other specialists.
Why It Works (Competitive Advantages)
- ✔First-in-class oral STAT1 inhibitor mechanism of action (MOA)
- ✔Potential for differentiated efficacy and safety profile in UC/CD
- ✔Strong intellectual property protection for obefazimod
Economic Moat: Narrow (Intangible Assets/IP (patent protection for obefazimod and its unique MOA))
What Our Analysis Says
DVR Score as of April 15, 2026
Abivax SA continues to exhibit significant 10x growth potential, primarily de-risked by obefazimod's positive DSMB review in its Phase 3 UC trial (90% complete, topline late Q2 2026). The substantial €530.4M cash position, secured through a recent offering, provides a runway to Q4 2027, mitigating immediate financial risk. The drug's differentiated oral, first-in-class STAT1 inhibitor profile still positions it for considerable market penetration if approved. However, the company faces persistent and widening net losses (€336.1M in FY 2025) and a pre-revenue valuation of $8.31B that already prices in substantial future success. Achieving a 10x return will demand exceptional clinical outcomes, aggressive commercial execution, and successful label expansion against a competitive landscape, alongside managing its high cash burn.